NCT03129724Unknown不适用
Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - Axitinib
University Hospital, Strasbourg, France0 个研究点目标入组 100 人开始时间: 2016年9月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 100
- 主要终点
- Evolution of Kidney cancer
研究概览
简要总结
Describe in patients with metastatic kidney cancer treatment modalities with the type sequences: TKI - mTORi - Axitinib or VEGF mAb - mTORi - Axitinib.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Evolution of Kidney cancer
时间窗: after surgery, up to 1 year]
次要结局
未报告次要终点
研究者
相似试验
终止
1 期
Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney CancerKidney NeoplasmsNCT00091611National Cancer Institute (NCI)3
Unknown
不适用
Metabolomic Profiling in Renal Cell CarcinomaRenal Cell CarcinomaNCT02001493Cambridge University Hospitals NHS Foundation Trust60
终止
4 期
Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)Renal Cell CarcinomaNCT02338570Mario Negri Institute for Pharmacological Research31
已完成
不适用
"Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC"Carcinoma, Renal CellNCT03538717Pfizer157
进行中（未招募）
2 期
Follow-up After Metastasectomy in Patients With Kidney CancerRenal Cell CarcinomaNCT00918775M.D. Anderson Cancer Center86